Skip to content
drillr.ai
Sign up

PFE

PFIZER INC

NYSE · Healthcare · Drug Manufacturers - General · US

$30.68
+2.27%
Ask drillr

  • Sep 4, 2026, 21:15 UTC

    Texas Attorney General Ken Paxton asked a federal appeals court to reinstate his lawsuit against Pfizer over COVID-19 vaccine efficacy claims, after a lower court dismissed the case on immunity grounds.

    Source:

  • Sep 3, 2026, 12:03 UTC

    Medicus Pharma Ltd. signed a Co-Development and License Agreement with Pfizer Inc., under which Pfizer granted Medicus an exclusive worldwide license to develop, manufacture and commercialize PF-08046031 (CD228V), with Medicus paying a $12.0 million upfront fee and Pfizer paying a $2.0 million development funding payment.

  • Aug 25, 2026, 09:55 UTC

    Bank of Nova Scotia reduced its stake in Pfizer Inc. by 13.4% during the quarter, selling 683,496 shares and retaining 4,423,296 shares, as disclosed in a 13F filing.

    Source:

  • Aug 23, 2026, 08:53 UTC

    Danske Bank A/S increased its stake in Pfizer Inc. by 9.2% during the second quarter of 2026, purchasing an additional 309,400 shares, as disclosed in its 13F filing with the SEC.

    Source:

  • Aug 23, 2026, 08:20 UTC

    Edmond DE Rothschild Holding S.A. sold 128,428 shares of Pfizer Inc., reducing its stake by 8.1% during the quarter, according to its SEC filing.

    Source:

  • Aug 22, 2026, 10:45 UTC

    BlackRock Inc. increased its stake in Pfizer Inc. by 6.3% during the second quarter, acquiring an additional 31,412,883 shares, as disclosed in its Form 13F filing with the SEC.

    Source:

  • Aug 22, 2026, 07:10 UTC

    AMG National Trust Bank reduced its stake in Pfizer Inc. by 30.2% during the second quarter of 2026, selling 27,369 shares and retaining 63,296 shares, as disclosed in a recent SEC filing.

    Source:

  • Aug 21, 2026, 09:15 UTC

    Russell Investments Group Ltd. increased its stake in Pfizer Inc. by 15.7% during the second quarter, acquiring 745,213 additional shares, according to its Form 13F filing.

    Source:

  • Aug 20, 2026, 10:04 UTC

    Ingrid Zhang, Chief Commercial Officer International at Novartis, decided to leave the company to pursue external opportunities, announced via an internal memo on August 19, 2026.

    Source:

  • Aug 20, 2026, 06:00 UTC

    Kenyan President William Ruto announced plans to meet Pfizer leadership to negotiate lower prices for life-saving medicines in Kenya.

    Source:

  • Aug 19, 2026, 09:15 UTC

    Central Carolina Community College opened the E. Eugene Moore Manufacturing and Biotech Solutions Center in Lee County, North Carolina, with a ribbon-cutting ceremony, unveiling the Kyowa Kirin Innovation Hub.

    Source:

  • Aug 17, 2026, 09:30 UTC

    Ballentine Partners LLC reduced its stake in Pfizer Inc. by 18.2% during the second quarter of 2026, selling 18,852 shares, according to a Form 13F filing.

    Source:

  • Aug 17, 2026, 08:57 UTC

    Elevated Capital Advisors LLC reduced its stake in Pfizer Inc. by 53.2% during the second quarter, selling 24,066 shares and retaining 21,185 shares, as disclosed in a recent SEC filing.

    Source:

  • Aug 17, 2026, 03:35 UTC

    The United States Court of Appeals for the Third Circuit affirmed the district court's summary judgment in favor of Sun Pharmaceutical Industries and its subsidiaries in antitrust litigation brought by plaintiffs over a 2008 patent settlement with Pfizer concerning generic Lipitor.

    Source:

  • Aug 14, 2026, 15:11 UTC

    Pfizer agreed to pay $44 million to settle a class action lawsuit over its smoking-cessation drug Chantix, which was approved by the FDA in May 2006 and taken off the market in 2021.

    Source:

  • Aug 14, 2026, 05:00 UTC

    The European Medicines Agency validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine candidate PF-07307405 and will begin its assessment.

    Source:

  • Aug 11, 2026, 12:00 UTC

    Pfizer and Astellas launched a joint grant program for independent medical education on urothelial cancer, with a total budget of US$450,000 and individual grants of US$10,000 to US$150,000, targeting healthcare professionals outside the United States.

    Source:

  • Aug 6, 2026, 13:59 UTC

    Pfizer discontinued two obesity drug candidates, MET-224o and PF-07976016.

    Source:

  • Aug 6, 2026, 11:00 UTC

    Genevant and Arbutus received $950 million from Moderna in July 2026 under a $2.25 billion settlement, with additional $1.3 billion contingent on appeal resolution, and filed new international lawsuits against Pfizer and BioNTech covering 21 jurisdictions.

    Source:

  • Aug 5, 2026, 12:15 UTC

    Pfizer is seeking a new chief financial officer as Dave Denton is set to depart later this month.

    Source:

  • Aug 4, 2026, 10:57 UTC

    Pfizer plans to advance the Phase 3 program for berobenatide this year, which includes 10 studies targeting chronic weight management and obesity-related conditions.

    Source:

  • Jul 31, 2026, 17:45 UTC

    Pfizer is pursuing a position in the obesity-drug market through its acquisition of Metsera and a broader GLP-1 pipeline.

    Source:

  • Jul 16, 2026, 11:30 UTC

    Arbutus Biopharma and its licensee Genevant filed three international patent infringement lawsuits against Pfizer and BioNTech.

    Source:

  • Jun 30, 2026, 21:52 UTC

    Nike appointed Dave Denton, formerly CFO of Pfizer, as its new Finance Chief.

    Source:

  • Jun 19, 2026, 15:25 UTC

    Pfizer's CFO Dave Denton announced his exit from the company.

    Source:
← PreviousPage 3Next →